Literature DB >> 33128769

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.

Frits van Rhee1, Jean-François Rossi2, David Simpson3, Alexander Fosså4,5, Angela Dispenzieri6, John Kuruvilla7, Yeow Tee Goh8, Seok-Goo Cho9, Marcelo Capra10, Ting Liu11, Corey Casper12,13,14, James Cavet15, Raymond S Wong16.   

Abstract

Entities:  

Keywords:  multicentric Castleman disease; siltuximab

Year:  2020        PMID： 33128769      PMCID： PMC7820993          DOI： 10.1111/bjh.17177

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  13 in total

Review 1.  The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care.

Authors:  Corey Casper
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

2.  Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.

Authors:  Frits van Rhee; Corey Casper; Peter M Voorhees; Luis E Fayad; Damilola Gibson; Karan Kanhai; Razelle Kurzrock
Journal:  Lancet Haematol       Date:  2020-02-03       Impact factor: 18.959

3.  Siltuximab for multicentric Castleman disease.

Authors:  Yi-Chang Liu; Katie Stone; Frits van Rhee
Journal:  Expert Rev Hematol       Date:  2014-08-09       Impact factor: 2.929

4.  Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.

Authors:  Frits van Rhee; Katie Stone; Susann Szmania; Bart Barlogie; Zeba Singh
Journal:  Clin Adv Hematol Oncol       Date:  2010-07

Review 5.  The soluble interleukin 6 receptor: mechanisms of production and implications in disease.

Authors:  S A Jones; S Horiuchi; N Topley; N Yamamoto; G M Fuller
Journal:  FASEB J       Date:  2001-01       Impact factor: 5.191

Review 6.  FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.

Authors:  Albert Deisseroth; Chia-Wen Ko; Lei Nie; Jeanne F Zirkelbach; Liang Zhao; Julie Bullock; Nitin Mehrotra; Pedro Del Valle; Haleh Saber; Christopher Sheth; Brenda Gehrke; Robert Justice; Ann Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2015-01-19       Impact factor: 12.531

Review 7.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

Review 8.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

9.  The clinical spectrum of Castleman's disease.

Authors:  Angela Dispenzieri; James O Armitage; Matt J Loe; Susan M Geyer; Jake Allred; John K Camoriano; David M Menke; Dennis D Weisenburger; Kay Ristow; Ahmet Dogan; Thomas M Habermann
Journal:  Am J Hematol       Date:  2012-07-13       Impact factor: 10.047

10.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476
View more
  1 in total

1.  How we manage idiopathic multicentric Castleman disease.

Authors:  Joshua D Brandstadter; David C Fajgenbaum
Journal:  Clin Adv Hematol Oncol       Date:  2022-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.